Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

Finally, Merck is an excellent dividend stock. It offers a juicy forward yield of 3.2% and has increased its payouts by 93.8% ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer. Merck has ...

Merck (NYSE:MRK) marked a major milestone in its bid to introduce a new formulation for its famous cancer therapy pembrolizumab on Tuesday as its blockbuster intravenous version, marketed as Keytruda ...

Merck's stock is suddenly soaring, but is the struggling healthcare giant a buy? Merck shares began peeling back in early ...

Merck & Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclitaxel) with or without Roche Holdings AG’s ...

Merck's updated narrative now anchors to a slightly higher fair value estimate of about $106.62 per share, up from roughly $104.27, as analysts grow more confident in the depth and durability of its ...

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...